C-UTS7targeted protein degradation, TRIM21 E3 ligase, aggregate-selective degraders
0-100 chain-logic scale · 15 dimensions · scored on public evidence
TrimTech Therapeutics targeted protein degradation, TRIM21 E3 ligase, aggregate-selective degraders
TRIMTECH Therapeutics is creating highly selective small molecule targeted protein degraders to combat neurodegenerative and inflammatory diseases. Its TRIMTAC and TRIMGLUE molecules recruit TRIM21, an E3 ligase, to disease-causing aggregated protein targets for degradation through the ubiquitin-proteasome system. The company's portfolio is focused on Alzheimer's, Parkinson's, Huntington's and other neurodegenerative and inflammatory disorders.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
TrimTech Therapeutics — Early mechanism · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (5 programs at preclinical).…
Source: Deterministic